Blood biomarkers in left-sided valvular heart disease

Augustin Coisne^{1

2}, Patrizio Lancellotti^{3

4}, Nancy Côté⁵, Julien Ternacle⁶, Sébastien Hecht⁵, Julia Grapsa⁷, Rebecca T Hahn⁸, Marie-Annick Clavel⁵, Mani A Vannan⁹, Brian Lindman¹⁰, Madalina Garbi¹¹, Cécile Oury³, Erwan Donal¹², Andrea Scotti¹³, Sebastian Ludwig^{2

14}, Adriana Postolache¹⁵, Patrick Myers¹⁶, Marc R Dweck¹⁷, Philippe Pibarot⁵

Affiliations

¹ Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Bd Pr Jules Leclercq, 59000 Lille, France.
² Cardiovascular Research Foundation, New York City, NY 10019, USA.
³ GIGA Metabolism and Cardiovascular Biology, University of Liège, Liège, Belgium.
⁴ Department of Cardiology, Heart Valve Clinic, University Hospital CHU Sart Tilman, Liège B-4000, Belgium.
⁵ Institut Universitaire de Cardiologie et de Pneumologie de Québec (Quebec Heart and Lung Institute), Université Laval, Quebec City, Quebec, Canada.
⁶ Service Médico-Chirurgical: Valvulopathies-Chirurgie Cardiaque-Cardiologie Interventionnelle Structurelle, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.
⁷ Guy's and St Thomas' NHS Trust Hospitals, London, UK.
⁸ Columbia University Medical Center/NY Presbyterian Hospital, New York City, NY 10032, USA.
⁹ Marcus Heart Valve Center, Piedmont Heart Institute, Atlanta, GA, USA.
¹⁰ Vanderbilt University, Nashville, TN, USA.
¹¹ Royal Papworth Hospital, Cambridge University Health Partners, Cambridge Biomedical Campus, Cambridge, UK.
¹² Cardiology Department, CHU de Rennes, Rennes, France.
¹³ Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College, Bronx, NY 10467, USA.
¹⁴ Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁵ CHU UCL Namur- Site Godinne, Namur, Belgium.
¹⁶ Hôpital de LaTour, Meyrin, Switzerland.
¹⁷ BHF Centre of Cardiovascular Science, The University of Edinburgh, Edinburgh, UK.

PMID: 40259754
DOI: 10.1093/eurheartj/ehaf232

Review

Blood biomarkers in left-sided valvular heart disease

Augustin Coisne et al. Eur Heart J. 2025.

. 2025 Jun 23;46(24):2289-2305.

doi: 10.1093/eurheartj/ehaf232.

Authors

Affiliations

¹ Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Bd Pr Jules Leclercq, 59000 Lille, France.
² Cardiovascular Research Foundation, New York City, NY 10019, USA.
³ GIGA Metabolism and Cardiovascular Biology, University of Liège, Liège, Belgium.
⁴ Department of Cardiology, Heart Valve Clinic, University Hospital CHU Sart Tilman, Liège B-4000, Belgium.
⁵ Institut Universitaire de Cardiologie et de Pneumologie de Québec (Quebec Heart and Lung Institute), Université Laval, Quebec City, Quebec, Canada.
⁶ Service Médico-Chirurgical: Valvulopathies-Chirurgie Cardiaque-Cardiologie Interventionnelle Structurelle, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.
⁷ Guy's and St Thomas' NHS Trust Hospitals, London, UK.
⁸ Columbia University Medical Center/NY Presbyterian Hospital, New York City, NY 10032, USA.
⁹ Marcus Heart Valve Center, Piedmont Heart Institute, Atlanta, GA, USA.
¹⁰ Vanderbilt University, Nashville, TN, USA.
¹¹ Royal Papworth Hospital, Cambridge University Health Partners, Cambridge Biomedical Campus, Cambridge, UK.
¹² Cardiology Department, CHU de Rennes, Rennes, France.
¹³ Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College, Bronx, NY 10467, USA.
¹⁴ Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁵ CHU UCL Namur- Site Godinne, Namur, Belgium.
¹⁶ Hôpital de LaTour, Meyrin, Switzerland.
¹⁷ BHF Centre of Cardiovascular Science, The University of Edinburgh, Edinburgh, UK.

PMID: 40259754
DOI: 10.1093/eurheartj/ehaf232

Abstract

Valvular heart disease (VHD) is a common condition that poses several challenges from the standpoints of diagnosis and therapeutic management. While several studies have explored the role of blood biomarkers in assessing the severity and risk of progression of VHD, as well as in evaluating related cardiac damage and predicting the occurrence of adverse events, blood biomarkers are generally not considered criteria to trigger valve intervention in the latest European and American guidelines for VHD management. This review article provides an up-to-date overview of the utility of blood biomarkers to (i) assess the presence, severity, and progression of left-sided VHD; (ii) establish the presence and extent of cardiovascular damage; (iii) predict clinical outcomes before and after valve interventions; and (iv) identify patients at risk for early structural valve deterioration, valve thrombosis, and paravalvular leak.

Keywords: Aortic stenosis; Blood biomarkers; Mitral regurgitation; Tricuspid regurgitation; Valvular heart disease.

© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Blood biomarkers in left-sided valvular heart disease

Affiliations

Blood biomarkers in left-sided valvular heart disease

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical